Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radiotherapy + anlotinib + microtubule inhibitor
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination treatment regimen is being evaluated in a Phase II clinical trial (NCT05493306) for the treatment of HER2-negative advanced breast cancer with brain metastases. The regimen consists of local radiotherapy (either stereotactic radiotherapy or whole-brain radiotherapy) combined with anlotinib, an oral multi-target tyrosine kinase inhibitor, and a microtubule inhibitor (such as eribulin or taxanes). Anlotinib targets several pathways involved in tumor angiogenesis and growth, including VEGFR, FGFR, PDGFR, and c-Kit. The microtubule inhibitor provides cytotoxic effects by disrupting tubulin polymerization or depolymerization, while radiotherapy provides local control of brain lesions. This multi-modal approach aims to improve intracranial and systemic disease control in a high-need patient population.
- Other names
- Radiotherapy Combined with Anlotinib and a Tubulin InhibitorRadiotherapy Combined with Anlotinib and a Microtubule InhibitorArloxitin + Radiotherapy + Tubulin Inhibitor
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on radiotherapy + anlotinib + microtubule inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radiotherapy + anlotinib + microtubule inhibitor.